The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our ...

Paragon 28's stock has seen a significant recovery from its low point of $4.89 in the third quarter of 2024, with InvestingPro data showing an impressive six-month return of 38.4%.

Zimmer Biomet has signed a definitive agreement to acquire Paragon 28 for an enterprise value of approximately $1.2bn, which will significantly bolster the former’s foot and ankle offerings.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer ...

Zimmer Biomet recently announced entering a definitive agreement to acquire all outstanding common shares of Paragon 28. Under the agreement, Zimmer Biomet will pay $13.00 per share, valuing ...

NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

Paragon 28 shares rose 8.4% after Zimmer Biomet Holdings agreed to acquire the company. Shares were trading around $13.02. The stock is up about 2.6% over the last year. Zimmer, a medical ...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of ...